Your session is about to expire
← Back to Search
CAR-T Therapy for Acute Lymphoblastic Leukemia
Study Summary
This trial tests if CAR-T therapy is safe and effective in treating B-ALL patients in remission with minimal disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 105 Patients • NCT02601313Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research currently seeking participants?
"Affirmative, clinicaltrials.gov data suggests that enrollment for this medical trial is presently open. It was first posted on November 15th 2023 and last updated a day later. The study requires 60 patients from 1 clinic to participate."
Is Autologous CAR T-cell immunotherapy a reliable form of treatment for patients?
"Autologous CAR T-cell immunotherapy holds a 2 rating on our 1 to 3 scale due to being in Phase 2 of the trial period, where safety has been demonstrated but efficacy is yet unproven."
How many participants are being recruited for the medical research?
"Affirmative. According to information accessible on clinicaltrials.gov, this research study is actively searching for volunteers with the first posting having been made on November 15th 2023 and edited one day later. Sixty patients are needed at a single site."
Share this study with friends
Copy Link
Messenger